Partnerships & Mergers

It builds on an earlier MoU signed by the two organisations in 2022 and sets out areas for deeper collaboration on health system strengthening and emerging health challenges.

The agreement establishes a framework for joint action against Bundibugyo virus disease, viral haemorrhagic fevers, cholera and other infectious disease threats that could spread across the border.

The acquisition brings MLM’s laboratory infrastructure and scientific expertise into Labcorp’s global network, creating a broader platform to support clinical trials across multiple regions.

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.

The hospital will coordinate the collection, while Sidra Medicine will process and store the samples at its specialized Good Manufacturing Practice (GMP) facility, which houses Qatar’s only cord blood bank.

Biohaven is currently evaluating the therapy in the Phase II/III RISE3 study, with results expected in the second half of 2026.

The agreement covers 129 countries, including all African nations, and gives Aspen rights across both public and private healthcare sectors.

Through its collaboration with Thmanyah, Bupa Arabia aims to make discussions about health and wellbeing more relevant to people’s everyday lives.

The agreement builds on Peking University’s longstanding involvement in global health research and public health capacity development.